文献类型：期刊文献

英文题名：Calcineurin inhibitors in the treatment of primary focal segmental glomerulosclerosis A protocol of systematic review and meta-analysis of randomized controlled trials

作者：Xue, Guozhong[1];Wang, Xinbin[1];Li, Shuwen[1];Dai, Enlai[1]

第一作者：薛国忠

通信作者：Dai, EL[1]

机构：[1]Gansu Univ Chinese Med, Lanzhou 730020, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Lanzhou 730020, Peoples R China.|[10735]甘肃中医药大学;

年份：2021

卷号：100

期号：4

外文期刊名：MEDICINE

收录：;Scopus(收录号：2-s2.0-85101191574);WOS:【SCI-EXPANDED(收录号:WOS:000612833500131)】；

基金：This study will be supported by the National Natural Science Foundation, No 81760799; Gansu University Finance Project, No.2305136302.

语种：英文

外文关键词：calcineurin inhibitors; meta-analyses; primary focal segmental glomerulosclerosis; randomized controlled trials; systematic review

摘要：Background: Evidence suggesting a role for including calcineurin inhibitors(CNIs) in early therapy remains limited for low quality and mainly based on small observation cohort study. We will conduct a systematic reviews to explore the effect and adverse effect of calcineurin inhibitors compared with other interventions in the treatment of primary focal segmental glomerulosclerosis (FSGS). Methods: A comprehensive literature search of MEDLINE (through PubMed), EMBASE, The Cochrane Library, Cochrane Central Register of Controlled Trials (CENTRAL) will be conducted. Two investigators will independently select studies, extract data and assess the quality of the included study. Extracted information will include study characteristics, the contents of included randomized controlled trials, outcomes, the quality of randomized controlled trials and etc. A risk of bias tool will be used to assess the methodological quality. Any disagreement will be resolved by the third investigator. There is no requirement of ethical approval and informed consent. Results: This study will provide high-quality evidence for treatment of FSGS in terms of effectiveness and safety. Conclusion: This systematic review aims to provide evidence for treatment of FSGS in different CNIs. Registration: The systematic review and meta-analysis is registered in the OSF REGISTERS (10.17605/OSF.IO/3B7DE) international prospective register of systematic review.